Company news

Ironwood Pharmaceuticals, Inc. news in 2026

Ironwood Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

November 5, 2026

Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance

November 5, 2026

Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call

October 28, 2026

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

October 16, 2026

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 3, 2026

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

August 6, 2026

Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call

July 30, 2026

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

July 14, 2026

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

May 27, 2026

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth, Maintains Full-Year 2026 Financial Guidance

May 8, 2026

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

May 7, 2026

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

May 4, 2026

Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

April 30, 2026

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

April 23, 2026

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

February 25, 2026

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call

February 18, 2026

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

January 1, 2026

Calls in 2026

Decks in 2026